* BioLife Solutions Inc BLFS.OQ BLFS.O is expected
to show a
rise in quarterly revenue when it reports results on May 10.
* The Bothell Washington-based company is expected to
report a
18.6% increase in revenue to $42.943 million from $36.22 million
a year ago, according to the mean estimate from 8 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for BioLife Solutions
Inc is
for a loss of 21 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had risen by
about 1.1%
in the last three months.
* Wall Street's median 12-month price target for BioLife
Solutions
Inc is $30, above its last closing price of $19.16.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2022 -0.20 -0.17 -1.15 Missed -590
Sep. 30 2022 -0.18 -0.17 -0.23 Missed -35.3
Jun. 30 2022 -0.23 -0.21 -0.06 Beat 72
Mar. 31 2022 -0.25 -0.25 -0.17 Beat 31.1
Dec. -0.16 -0.17 -0.37 Missed -119.5
31 2021
Sep. 30 2021 -0.09 -0.09 0.00 Beat 100
Jun. 30 2021 -0.09 -0.07 -0.12 Missed -80
Mar. 31 2021 -0.04 -0.04 -0.03 Beat 21.7
This summary was machine generated May 9 at 01:26 GMT. All
figures in US dollars unless otherwise stated